Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

AL-3778

Alternative Names: al-3778, al3778, al 3778
Latest Update: 2017-10-16
Latest Update Note: Clinical Trial Update

Product Description

Alios Biopharma was developing al-3778, an oral HBV-NART inhibitor, for the treatment of chronic hepatitis B (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03125213)

Mechanisms of Action: HBV-NART Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Alios Biopharma
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hepatitis B, Chronic|Hepatitis A

Phase 1: Hepatitis A|Hepatitis B, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
AL-3778-1003

P2

Withdrawn

Hepatitis A|Hepatitis B, Chronic

2019-02-15

AL-3778-1002

P1

Terminated

Hepatitis A|Hepatitis B, Chronic

2017-06-28

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions